ERBB2 and aneurysmal bone cyst: In conclusion, ARX788, a site-specific construct-homogeneous ADC, demonstrated a significant PFS benefit in the second-line treatment of HER2-positive ABC patients who had progressed on one line of trastuzumab based regimen and had been pretreated with taxane.